There is a consensus that patients with schizophrenia show a number of important differences from control subjects on a range of measures of brain structure and function. Computerised tomography (CT) scanning has repeatedly identified enlarged lateral ventricles and reduced brain substance, both in chronic cases and at initial presentation (Johnstone et a!, 1976; Daniel et a!, 1991). Magnetic resonance imaging (MRI) has established that medial temporal lobe structures are smaller in schizophrenic subjects than controls (Suddath et a!, 1990; Shenton et a!, 1992). Functional brain-imaging methods i.e., single photon emission tomography (SPET) and positron emission tomography (PET), have found reductions in regional cerebral blood flow or metabolism, particularly of the frontal lobes, in chronically ill and medicated patients (Ebmeier, 1994). Several researchers have described cognitive deficits in patients with schizophrenia, often in association with enlarged lateral ventricles (Johnstone et a!, 1976; Golden et a!, 1980 
structure and function. Computerised tomography (CT) scanning has repeatedly identified enlarged lateral ventricles and reduced brain substance, both in chronic cases and at initial presentation (Johnstone et a!, 1976; Daniel et a!, 1991) . Magnetic resonance imaging (MRI) has established that medial temporal lobe structures are smaller in schizophrenic subjects than controls (Suddath et a!, 1990; Shenton et a!, 1992) . Functional brain-imaging methods i.e., single photon emission tomography (SPET) and positron emission tomography (PET), have found reductions in regional cerebral blood flow or metabolism, particularly of the frontal lobes, in chronically ill and medicated patients (Ebmeier, 1994) . Several researchers have described cognitive deficits in patients with schizophrenia, often in association with enlarged lateral ventricles (Johnstone et a!, 1976; Golden et a!, 1980) . It is less clear how these biological variables relate to clinically relevant features of the illness. Of these, response to treatment is of central importance. While many patients make a virtually complete recovery from a discrete episode, repeated trials have found that up to 25% of patients derive relatively little benefit from typical neuroleptic drug therapy, and 6â€"8%fail to respond to many months or years of intensive antipsychotic treatment (May et a!, 1988). Optimal prediction of treatment response has obvious relevance for the clinical management of schizophrenia, and recent developments in brain imaging, along with renewed interest in neuropsycho logical measures of brain function, have increased the possibilities for investigations in this area. Several CT studies have examined the associations of treatment response or illness outcome, but usually in post hoc differentiated patient groups, and results have both supported and refuted a relationship between structural abnormality and worse response. There is a dearth of studies employing MRI, PET/SPET, or detailed neuropsychological testing to examine this issue. The purpose of this study was to use such methods, in dichotomised patient groups, to identify the associations of treatment response. MRI, SPET, and a comprehensive neuropsycho logical test battery were employed to test the hypothesis that treatment-resistant patients show more evidence of structural abnormality, functional underactivity, and cognitive deficit than treatment responsive patients. â€oe¿ psychotic symptoms or disturbed behaviour [that] does not remit such that they will remain for a long while in hospital or some alternative form of caring milieu [level 5] â€oe¿ . There were no patients at level 4. The two groups of 20 patients were matched for sex (10 male and 10 female in each group), age (within six years), and duration of illness (within six years). Patients were excluded if they suffered from any neurological condition, current substance abuse, or major depression, or were pregnant.
Clinical assessments
All 40 subjects underwent a detailed clinical examination comprising a structured psychiatric interview, the Present State Examination (Wing et a!, 1974);a standardised rating of current symptoms, the Manchester Symptom Scale (Krawiecka et a!, 1977) ; and a brief neurological examination to complete the Abnormal Involuntary Movement Scale (AIMS) and the Targeting Abnormal Kinetic Effects scale (TAKE; Wojcik et a!, 1980) . This was supplemented by information from the patients' psychiatric case-notes to complete the Schedule for Affective Disorders and Schizophreniaâ€"Lifetime Version, for Research Diagnostic Criteria (RDC; Spitzer & Endicott, 1978) , and a modified version of the DHSS Survey form (Johnstone, 1991) . Illness onset was defined as the age at first record of sufficient features to satisfy DSMâ€"IIIâ€"R diagnostic criteria for schizophrenia; the duration of illness was taken from this date until the beginning of the investigation in January 1992. Additional measurements of illness outcome were made from interview and case-note information. Social outcome (self-care, employment history, acceptability of behaviour) was assessed on the rating scale devised by Cooper (1961) , and global outcome was measured on the McGlashan cross-sectional and follow-up scales (McGlashan, 1984) .
Magnetic resonance imaging (MRI)
All 40 patients underwent MRI scanning on a 1.0 Tesla Siemens (Erlangen, Germany) scanner. Midline sagittal localisation was followed by two sequences to image the whole brain. A â€˜¿ Turboflash' sequence, a 3-D-FLASH collection 500 ms after a spin inversion (TI = 500 ms), produced an image that could be reconstructed in three dimensions. A spin echo (SE) dual-echo scan was also conducted, with a repetition time of 3656 ms, and echo times of 20 ms for a proton density-weighted image and 90 ms for a T2-weighted image (SE 3565/20â€"90) .The 3-D-FLASH sequence was collected as 128 contiguous 1.56 mm-thick coronal slices, with flip angle 10Â°, repetition time 10 ms, echo time 4 ms, field of view 255 mm, and relaxation delay 1 s. The SE scan generated 31 contiguous 5-mm-thick axial slices in the Talairach plane, with flip angle 90Â°and field of view 250 mm. Regular phantom measurements over the 15 months of the study ensured that these sequences remained reliable.
A clinical neuroradiologist (CGS) examined the MRI scans for structural abnormalities and motion artefact â€"¿ one subject was rescanned because his first scan was severely degraded by movement.
Image processing was done on Sun Microsystems workstations with the software package â€˜¿ Analyze' (Mayo Foundation, Rochester, MN, USA) to outline and compute volumes of neuroanatomical structures. Structures were identified with the assistance of an MRI atlas, and volumes were calculated by summing voxels on all slices included. Specific regions of interest selected a priori were prefrontal lobes (left and right), temporal lobes (left and right), hippocampi (left and right), whole brain, intracranial cerebrospinal fluid (CSF),lateral ventricles (left and right), and third and fourth ventricles (combined). The prefrontal lobes were defined as by Suddath et a! (1990) , the temporal lobes and hippocampi were defined according to the method of Shenton et a! (1992) , and the remaining regions of interest were outlined by naturalistic boundaries. The 3-D-FLASH scans were used for all measurements except the whole-brain and intracranial CSF volumes, which were calculated from the SE 3565/20â€"90 scans after ensuring that whole-brain volumes derived by both methods were similar (interscan correlation r= 0. 
Single photon emission tomography (SPET)
SPET imagingwas done on a dedicated SME-Multi X8l0 Strichman brain scanner, @Â°â€˜Tc-Exametanime (HMPAO) being used to measure regional cerebral perfusion. Traceruptake was measured as count density on slices at 5-mm intervals, extending the full length of thebrain(14â€"18 slices persubject). Three slices were used in this study: at the midventricular level (including the basal ganglia) 4cm above the orbitomeatal line (OML), and 6 and 8 cm abovethe OML, to give 36 regions of interest (Table 2) . A standardised brain template, derived from an atlas, was symmetrically and linearly transformed to fit the brain outline defined by 4001oof the image intensity spectrum, and regional reconstructed count densities were computed on SME 810 software2.61.
Neuropsychological testing battery
Comprehensive testing was undertaken with a wide variety of tasks, chosen because executive and mnemonic deficits havebeenfrequently reported in schizophrenic subjects and for ease of application inthis population. These included globalmeasures of premorbid intellectual ability, i.e. the National Adult Reading Test(NART); currentIQ, i.e. the Quick Test; global intellectual functioning, i.e. the Mini-Mental State Examination (MMSE); attention/working memory, i.e. the Digit Span (forward and backward) and psychomotor speed, i.e. Digit Symbol Substitution, from the Wechsler Adult Intelligence Scaleâ€"Revised (Wechsler, 1981). Tests ofexecutive functioning included verbal fluency, or word production, for animals and for words beginning withtheletter A in60 s;theStrooptest; and Trails A and B. The Annettscale was chosen to measure handedness. The profile score of the RivermeadBehavioural Memory Test(RBMT) was used as an index of episodic memory. Selected measuresfrom theCambridge Neuropsychological Testing Automated Battery (CANTAB) were also employed. Finally, the tester ratedthe patients' attention and cooperation on two five-point scales.
The results from all these measures will be reported indetail elsewhere (Rogers eta!, inpreparation), only themain findings and their clinical and biological associations being given in this paper.
Timing of investigations and data analysis
The SPET scangenerally followed MRI withinone week (median interval six days), and the neuropsychological and clinical assessments were usually completedintwo sittings, within a few days of the SPET scan (median interval six days). The results wereanalysed by SPSS forMac 4.0.As age, sex, and duration of illness were matched between groups at the design stage, the effects of these variables were not examined. Multivariate analysis of variancewas conducted,the 11 MRI regional volumes and 36 SPET regional tracer uptake ratios beingtreated asrepeated measures. The MRI results were analysed as both absolute volumesand,after correction for whole-brain volume, to control for variations inheadsize, while SPET tracer uptakewas analysed after normalisation to both whole slice or occipital uptake ratios. The effects of laterality and region on structure volumes were examined with two â€˜¿ between factors' (treatment-response group membership and sex) and two â€˜¿ within factors'
(laterality and region), followed by a t-test for individual regions of interest. Effect sizes (as standardised differences) were calculated for 
Results

Clinical characteristics
The DSMâ€"IIIâ€"R diagnostic categories were as follows: Schizophreniform Psychosis(n= 2) and Schizophrenia (n = 38), with subcategories of Paranoid (n = 19), Undifferentiated (n = 10), 
MRI
The hippocampi could not be measured in two male subjects because of movement artefact, but the remaining structures were reliably identifiable inall scans. The mean height oftheresistant patients, at 167.8 cm, was lower but not significantly different from that of the responsive patients, at 169.4cm (P= 0.6). Analysis between response groups by MANOVA found no significant differences in the volumes of any measured structure, comparing either raw volumes (F1,38= 1.1, P=0.3) or those corrected for whole-brain volume (F1,38=0.2, P= 0.9). Table 1 shows the absolute volumes of thestructures measured,together witheffect sizes ofthedifferences betweenresponse groups. Almost all structures were smaller in the treatment-resistant group, with only the minor exceptionsof the left prefrontal lobe and the third/fourth ventricles. There was no interaction between response and region, but therewas a tendencyto one between response and side (F1,38= 3.0, P= 0.09). Post hoc paired t-tests, across all subjects, revealed smaller left-thanright-sided hippocampi(two-tailed t= 3.03, P= 0.004) and temporal lobes (two-tailed t = 1.93, P = 0.06). Analysis of the effects of sex revealed significantly smaller volumes of all structures in women (F338 = 7.44, P= 0.01), but no interaction with response, region or side. Left-handed subjects (n = 4), had lower volumes of all structures than the right-handers (ii = 35; one ambidextrous), but this difference was statistically significant only in the left temporal lobe (raw volumes 68.2 versus 76.6 cc; two-tailed t = 3.26, P= 0.01).
SPET
The overall effect of illness outcome on regional uptakeratios failed to reachstatistical significance by MANOVA, whetheruptakewas normalised to the whole slice (F1,38=0.98, P=0.5) or occipital uptake (F1,38 = 2.06,P= 0.3). Table 2 shows the uptake ratios, normalised to whole slice uptake, in the 36 regions of interest from the three slices analysedin thisstudy.
stable at the time of the investigations, so that the effects of acuterelapse, large dosesof medication, or both were minimised.
The matchingof patients forsex(10male and 10 female patients in each group),age (responsive patients mean 36.5(s.d. 9.9) years, resistant patients mean 34.7(10.3) years), and illness duration (mean 139.3 (105.05) months and 150.8 (106.0) months, respectively) was satisfactory, althoughtreatment resistant patients were younger and yet had been ill forlonger, indicating an earlier ageatonsetinthis group. As would be expected, the mean number of admissions (4.9 (4.7) versus 10.4 (6.5)), total time spent in hospital (6.6 (7.1) months versus 57.1(87.4)) and current antipsychotic medication dosage (268 (274) mg chlorpromazine equivalents versus 902
(669) mg) were substantially higher in treatment resistant patients. The mean current anticholinergic medication dosage, in procyclidine equivalents, was similar in both groups (3.0 (6.4) versus 3.3 (4.7)).
Paternal occupation (social class) was also similar Table 2 SPETregionaluptakeof @â€oe¿ Tc-exametazime, normalised to wholeslice,in responsive and resistantschizophrenic
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patients (mean and standard deviations)
No significant correlations werefoundbetween current neuroleptic medication dosage (in chlorpromazine mg equivalents) and either MRI regional structure volumes or SPET regional tracer uptake (normalised to occipital uptake).
Neuropsychology
Some patients did not complete all the testing, but only one refused to do every test. Several statistically significant differences emerged between the two response groups, indicating poorer functioning in treatment-resistant patients (Fable 3). However, after the number of years spent in full-time education was controlled for by ANCOVA, only one measure differed significantly between responsive and resistant patients, i.e.the RBMT profilescore (F1,35=9.7,P=0.004). This test showed a statistically significant difference between the groups, even when years in education, NART determined Table 3 Neuropsychological tests which distinguished between groups in responsive and resistant schizophrenia (means and standard deviations) Table 3 shows the between-group differences both before and after controlling for years spent in education to allow the reader to examine the magnitude of the effect.
ainical and biologicalcorrelations
As shown inTable4, Spearman rank correlations were fairly strong among the MRI whole-brain, temporal, andprefrontal lobe volumes (particularly the left side) and many neuropsychological test 
Discussion
The principal finding of this study is that treatment resistant schizophrenic patients in comparison with treatment-responsive patients, have neither a statistically significant lower volume of brain structures with MRI nor reduced tracer uptake with
SPET.
However, several differences were found between the groups on neuropsychological testing, and the most discriminating test, the RBMT, remained significant after controlling for several possible confounders. Therearea number ofpossible reasons for the negative findings on the brain scans, including insufficient dichotomisation of the patient groups, inadequate statistical power, and lack of biological differences between such patient groups and/or the masking of any differences between subtypes by the heterogeneity inherent in schizophrenia. (Weinberger, 1987) . If this model isaccurate, the main problem in detecting subtle differences between patients and controls, and even smaller differences between patient subgroups, is in study power.
The largest effect size of MRI variables between response groups in this study was 0.46 for the right temporallobe volume difference; 80% power to detecta statistically significant difference in this variable would demand two groupsof 75 patients. The patient groupsinthis studydiffered markedly in terms of â€˜¿ positive symptoms' but less so in the levels of â€˜¿ negative symptoms'. Positive symptoms, particularly delusions and hallucinations, havebeen linked to pathological processespredominantly affecting neuronal networks in temporolimbic MRI studies have demonstrated reduced superior temporal gyral volume in schizophrenic subjects as compared with controls (Barta et a!, 1990; Shenton eta!1992) , although these abnormalities aregenerally thoughtto be more marked in the left than right hemisphere. These results are supported by the relatively strong correlations between temporal volumes and the clinical/neuropsychological results found here. The less marked between-group difference innegative symptoms couldaccountfor the failure to find larger differences in the volumes ofotherstructures, particularly thelateral ventricles, whichwerequite strongly correlated withthefactor composed of threenegative symptoms (factor 2).
The results from CT studies examining the relationship between structural abnormalities, usuallylateral ventricular enlargment,and poor outcomehavebeenconflicting. Inthestudies directly examining this issue, two main approaches have been used. Schizophrenic patients have been selected fora particularly highventricle brainratio (VBR) (usually two standard deviations above a control group mean) or not, before treatment, A volumetric rather than area approach, using MRI rather than CT, in specifically selected patients, should more powerfully determine the relationship betweenneuroanatomyand outcome or treatment response. Certainly, previous MRI studies suggest an association between increased ventricular size and poor outcome (Johnstone eta!,1989 ;DeLisieta!, 1992), or more negative symptoms (Young et a!, 1991; Gur et a!, 1994) , and between reduced mesiotemporal volumes and more severe positive symptoms (Bogerts et a!, 1993 (Harvey et a!, 1993) .These results are consistent with the findings of this study that there isonlya weak relationship betweenbrainstructure and clinical outcome in most patients with schizophrenia.
The possibility remains that a subgroup of schizophrenic patients withmarked structural brain changes could be delineated.
This would be compatible with the great variability in MRI volumes within patient groupsinthis study, whichwas more marked inthetreatment-resistant group.Previous studies ofpatients withparticularly large ventricular areashavegenerally foundthattheyrespondpoorly to treatment (see above), but patients with schizophrenia do not have a bimodal distribution of VBR on CT (Daniel et a!, 1991) , suggesting that ventricular enlargement isnota markerfora specific subtypeof schizophrenia.
Inthis study, althoughimagingvariables didnot distinguish the patient groups, cognitive testing, particularly of long-term memory functioning (RBMT), did do so.Several previous studies have shown that schizophrenic subjects have cognitive deficits, primarily of memory, learning, and concept formation, ascompared withcontrols (Goldberget a !, 1990; Frith eta!, 1991; Saykin eta!, 1991) . Indeed, further evidence suggests that schizophrenic patients exhibit a relatively specific pattern of neuro psychological abnormality â€"¿ primarily that of impaired long-term memory â€"¿ akin to a dysmnesic syndrome, and thatthesedeficits are related to outcome measures (Goldberg et a!, 1990; Tamlyn et a!, 1992; Goldberg et a!, 1993) . However, there arealsoreports ofspecific impairments inexecutive tasks (Shallice eta!, 1991) . The results from this study confirm findings of particular deficits in memory, and suggestthatthesemay even be a relatively specific marker for poor outcome. For example, memory impairment may adversely affect treatment compliance or hinder abilities on several everyday tasks. Although the RBMT profile score correlated more strongly withpositive thannegative syndrome scores, the loading onto both factors 1 and 2 suggests that this may simply reflect that these measures best distinguished the patient groups. The correlations betweentheneuropsychological results and several regional volumes are compatible with evidence that neuropsychological deficits reflect generalised cerebral dysfunction, but that this is most pro nounced in temporal areas and memory functions (Goldberg et a!, 1990 ).
In conclusion, the ability of episodic memory tests to distinguishsubgroups of patients with schizophrenia suggests thatmemory functioning is an important determinant of outcome in schizophrenia.
Morphological differences are detectable between treatment-responsive and treatment-resistant patientgroups,but relatively large study groups would be required to differentiate them by neuroimaging methods. Neuropsychological testing might be better able to delineate prognostic and even aetiological subtypes of schizophrenia. The possibility that there is a subtype of schizophrenia associated with clearly abnormal cerebral structure and poor outcome cannot be excluded, but the findings of this and other studies suggest that illness outcome -or even treatment response -is confounded by too many variables to be predicted by currently available imaging methods. The variability in other illness factors in schizophrenia appears to be greater thanthatrelated tooutcome ortreatment response. 
